Side‐effects of carbetocin to prevent postpartum hemorrhage: A systematic review and meta‐analysis of randomized controlled trials
Open Access
- 15 March 2021
- journal article
- review article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 9 (2) , e00745
Abstract
Postpartum hemorrhage (PPH) increases the risk of maternal death worldwide. Heat‐stable carbetocin, a long‐acting oxytocin analog, is a newer uterotonic agent. Clinicians do not fully understand its side‐effects, particularly the unanticipated side‐effects. The aim of this study is to investigate the side‐effects of carbetocin to PPH. The Cochrane Library, Web of Science, PubMed, Elsevier ScienceDirect, Embase, and ClinicalTrials.gov were searched from the inception to September 2020. Randomized controlled trials (RCTs) that considered pregnant women who received carbetocin before delivery and provided at least one adverse event were included. Statistical analysis included random or fixed‐effect meta‐analyses using relative risk. Stratified analyses and sensitivity analyses were also performed. Begger's and Egger's test and funnel plots were used to assess the publication bias. Seventeen RCTs involving 32,702 women were included, and all these studies ranked as medium‐ to high‐quality. Twenty‐four side‐effects were reported. The use of carbetocin had a lower risk of vomiting in intravenously (0.53, 0.30 to 0.93) and cesarean birth (0.51, 0.32 to 0.81) women, and had a slightly higher risk of diarrhea (8.00, 1.02 to 62.79) compared with oxytocin intervention. No significant difference was found among other side‐effects. Evidence from our systematic review and meta‐analysis of 17 RCTs suggested that the risk of vomiting decreased with carbetocin use in the prevention of PPH after delivery.Keywords
This publication has 30 references indexed in Scilit:
- Carbetocin versus oxytocin for prevention of postpartum hemorrhage after vaginal delivery in high risk womenThe Journal of Maternal-Fetal & Neonatal Medicine, 2015
- Global causes of maternal death: a WHO systematic analysisThe Lancet Global Health, 2014
- Changes in Blood Pressure and Cardiac Output during Cesarean DeliveryAnesthesiology, 2013
- Estudio clínico y farmacoeconómico de la eficacia de la carbetocina en cesáreas electivas respecto a la oxitocina a dosis bajas y a dosis habitualesRevista Española de Anestesiología y Reanimación, 2013
- Carbetocin for preventing postpartum haemorrhage2012
- Does carbetocin for prevention of postpartum haemorrhage at caesarean section provide clinical or financial benefit compared with oxytocin?Journal of Obstetrics and Gynaecology, 2011
- Haemodynamic effects of carbetocin and oxytocin given as intravenous bolus on women undergoing caesarean delivery: a randomised trialBJOG: An International Journal of Obstetrics & Gynaecology, 2011
- Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double‐blind randomised trialBJOG: An International Journal of Obstetrics & Gynaecology, 2010
- Utilization of carbetocin for prevention of postpartum hemorrhage after cesarean section: a randomized clinical trialArchives of Gynecology and Obstetrics, 2009
- Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterusClinical Pharmacology & Therapeutics, 1992